SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-01

Study Completion Date

2025-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

NCT05436639

Autonomous Cortisol Secretion (ACS) ACTH-Independent Cushing Syndrome ACTH-Independent Adrenal Cushing Syndrome, Somatic

TERMINATED PHASE2

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

NCT02804750

Cushing's Syndrome

COMPLETED PHASE2

Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia

NCT03257462

Congenital Adrenal Hyperplasia CAH - Congenital Adrenal Hyperplasia

COMPLETED PHASE2

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

NCT00796783

Cushing's Syndrome

TERMINATED

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

NCT06430528

Endogenous Cushing Syndrome Adrenal Insufficiency Hypercortisolism

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, randomized, placebo-controlled, Phase 2 study to evaluate the pharmacologic effect, efficacy, and safety of SPI-62 in subjects with ACTH-dependent Cushing's syndrome. Each subject who provides consent and meets all inclusion and exclusion criteria will participate in a screening period (Days -35 to -8), a baseline period (Days -7 to -1), and a treatment period (Day 1 of Week 1 to Day 168 ± 3 days of Week 24) and, the option of long-term extension. Subjects have the option to continue with the study on active study drug and return to the site every 3 months for blood tests and study drug dispensing. The visits may be conducted remotely if testing can be arranged.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cushing's Syndrome I Cushing Disease Due to Increased ACTH Secretion Cortisol Excess Cortisol; Hypersecretion Cortisol Overproduction Ectopic ACTH Secretion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Staggered parallel crossover

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SPI-62

Active drug by mouth each morning for up to 12 weeks

Group Type EXPERIMENTAL

SPI-62

Intervention Type DRUG

11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor

Placebo

Intervention Type DRUG

Inactive tablets identical to SPI-62 tablets

Placebo

Placebo by mouth each morning for up to 12 weeks

Group Type PLACEBO_COMPARATOR

SPI-62

Intervention Type DRUG

11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor

Placebo

Intervention Type DRUG

Inactive tablets identical to SPI-62 tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SPI-62

11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor

Intervention Type DRUG

Placebo

Inactive tablets identical to SPI-62 tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or non-menstruating female
* 18 years or older
* Active and consistent cortisol excess
* Documented diagnosis of ACTH-dependent Cushing's syndrome including Cushing's disease, ectopic ACTH secretion, and ectopic CRH secretion.

Exclusion Criteria

* Recent (within 6 weeks) surgery for Cushing's or surgery planned within 24 weeks of randomization.
* History of any fractionated radiation therapy for Cushing's within the past 2 years or conventional radiation therapy within 4 years.
* History of bilateral adrenalectomy or exogenous, pseudo, cyclic, or non-ACTH-dependent Cushing's syndrome (including certain inherited conditions).
* High risk of acute morbidity from corticotroph adenoma growth (similar to that which occurs with Nelson's syndrome) defined as current evidence of macroadenoma at risk of impingement of vital structures.
* Any current or prior medical condition, medical or surgical therapies, or clinical trial participation expected to interfere with the conduct of the study or the evaluation of its results, including but not limited to poor venous access or recent receipt or donation of blood products.
* Women who are currently pregnant, lactating or planning fertility and unwilling to adhere to approved contraceptives or abstinence.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No